Trust Stamp Inc's Maltese subsidiary, Trust Stamp Malta Limited, has joined the EU's Important Project of Common European Interest on Advanced Semiconductor Technologies (IPCEI AST). This initiative aims to strengthen Europe's semiconductor industry by accelerating next-gen chip development and deployment. Trust Stamp will contribute its privacy-first identity technology, linking device identity to verified human identity using hardware-rooted security and biometric tokenization. The participation includes two cooperation agreements from 2027 to 2032, focusing on secure semiconductor identity platforms and AI-assisted neural-signal data processing. This involvement positions Trust Stamp within a key EU industrial program, supported by Malta Enterprise, enhancing local tech ecosystems and advancing secure hardware authentication.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
